TY - JOUR
T1 - Glaucoma treatment with once-daily levobunolol
AU - Wandel, Thaddeus
AU - Charap, Arthur D.
AU - Lewis, Richard A.
AU - Partamian, Leon
AU - Cobb, Stephen
AU - Lue, John C.
AU - Novack, Gary D.
AU - Gaster, Ronald
AU - Smith, Jess
AU - Duzman, Efraim
PY - 1986/3/15
Y1 - 1986/3/15
N2 - Although twice-daily instillation of topical beta-blockers is the standard regimen for treatment of increased intraocular pressure, once-daily therapy might improve patient compliance and provide greater safety. In a three-month, double-masked clinical trial, 92 patients with open-angle glaucoma or ocular hypertension received levobunolol 0.5% or 1% or timolol 0.5% once daily, in both eyes. Overall mean decreases in intraocular pressure were significantly greater in the groups treated with levobunolol than in the group treated with timolol. Intraocular pressure decreases averaged 7.0 mm Hg with levobunolol 0.5%, 6.5 mm Hg with levobunolol and 4.5 mm Hg with timolol. The intraocular pressures of 72% (18 of 25 patients) of those treated with levobunolol 0.5%, 79% (22 of 28 patients) of those treated with levobunolol 1%, and 64% (16 of 25 patients) of those treated with timolol were successfully controlled during the study. Heart rate and blood pressure decreases were minimal with both levobunolol and timolol. Study results indicated that once-daily treatment with levobunolol and, to a lesser extent, timolol is sufficient to control intraocular pressure successfully and safely.
AB - Although twice-daily instillation of topical beta-blockers is the standard regimen for treatment of increased intraocular pressure, once-daily therapy might improve patient compliance and provide greater safety. In a three-month, double-masked clinical trial, 92 patients with open-angle glaucoma or ocular hypertension received levobunolol 0.5% or 1% or timolol 0.5% once daily, in both eyes. Overall mean decreases in intraocular pressure were significantly greater in the groups treated with levobunolol than in the group treated with timolol. Intraocular pressure decreases averaged 7.0 mm Hg with levobunolol 0.5%, 6.5 mm Hg with levobunolol and 4.5 mm Hg with timolol. The intraocular pressures of 72% (18 of 25 patients) of those treated with levobunolol 0.5%, 79% (22 of 28 patients) of those treated with levobunolol 1%, and 64% (16 of 25 patients) of those treated with timolol were successfully controlled during the study. Heart rate and blood pressure decreases were minimal with both levobunolol and timolol. Study results indicated that once-daily treatment with levobunolol and, to a lesser extent, timolol is sufficient to control intraocular pressure successfully and safely.
UR - http://www.scopus.com/inward/record.url?scp=0022578839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022578839&partnerID=8YFLogxK
U2 - 10.1016/0002-9394(86)90823-8
DO - 10.1016/0002-9394(86)90823-8
M3 - Article
C2 - 3513594
AN - SCOPUS:0022578839
SN - 0002-9394
VL - 101
SP - 298
EP - 304
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 3
ER -